Related Experiment Video
Updated: Jul 13, 2025
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Clinical advances in oncolytic virus therapy for malignant glioma: a systematic review
Shan Jiang1,2,3,4, Huihui Chai1,2,3,4, Qisheng Tang1,2,3,4
1National Center for Neurological Disorders, Shanghai, China.
Purpose:
In the past decade, there has been little progress in the treatment of malignant glioma. Recently, oncolytic virus has made great progress in glioma treatment, and a number of clinical trials have shown their potential of prolonging the survival time of glioma patients. Our objective is to evaluate effectiveness and safety of oncolytic virus (OV) in malignant glioma treatment.
Methodology:
Based upon PRISMA, we collected relevant published clinical trials by searching medical databases up to January 16, 2023, applying the language restrictions in English and Chinese. We cross-searched the terms: 'glioma', 'glioblastoma', 'oncolytic viruses', 'oncolytic virotherapy' with filter 'clinical trial'. Two researchers independently extracted the data regarding case definitions, published years, trial phase, characteristics of patients, administration of drug, overall survival (OS), and adverse events.
Results:
19 published clinical trials in OV treatment of malignant glioma were included in the further systematic review analysis. None of them induced irresistible adverse effects attributing to OV treatment, median overall survival varied from 3.25 to 20.2 months after treatments. According to trials providing patient's detailed molecular diagnosis, we find that the effectiveness of OV treatment has no significant difference in patients with different IDH or MGMT status.
Conclusions:
Current clinical trials have initially shown the potential of oncolytic virotherapy as a new treatment for malignant glioma. Besides development of virus types, the strategy of OV use is an urgent problem to be solved in future clinical application, such as repeated administrations, innovative drug delivery systems, and biomarkers.
Insights
Oncolytic virus (OV) therapy shows promise for malignant glioma treatment, demonstrating potential to prolong survival without severe adverse effects. Further research is needed on optimal OV application strategies for improved clinical outcomes.
Area of Science:
- Neuro-oncology
- Virology
- Clinical Trials
Background:
- Malignant glioma treatment has seen limited progress over the last decade.
- Oncolytic viruses (OV) have emerged as a promising therapeutic strategy for glioma.
- Clinical trials indicate OV therapy's potential to extend survival in glioma patients.
Purpose of the Study:
- To systematically evaluate the effectiveness and safety of oncolytic virus (OV) therapy in malignant glioma.
- To analyze data from published clinical trials on OV treatment for glioma.
Main Methods:
- A systematic review of published clinical trials was conducted up to January 16, 2023.
- Searches included terms like 'glioma,' 'glioblastoma,' and 'oncolytic viruses' in English and Chinese.
- Data extraction focused on survival outcomes and adverse events from 19 selected trials.
Main Results:
- Nineteen clinical trials involving OV treatment for malignant glioma were analyzed.
- No treatment-related irresistible adverse effects were reported.
- Median overall survival ranged from 3.25 to 20.2 months.
- OV treatment effectiveness did not significantly differ based on IDH or MGMT molecular status.
Conclusions:
- Oncolytic virotherapy represents a potential new treatment modality for malignant glioma.
- Future clinical applications require optimized strategies, including virus development, administration schedules, drug delivery systems, and biomarkers.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...